USA News Group
Commentary
Issued on behalf of Oncolytics Biotech
Inc.
VANCOUVER, BC, Dec. 26,
2024 /PRNewswire/ -- USA News Group News Commentary
– Immunotherapy is transforming oncology by harnessing the immune
system's power to fight cancer like never before. Notable
advancements include a bioengineered therapeutic platform that
boosts immune responses, providing targeted solutions for
challenging cancer types. Researchers have also introduced an
mRNA-based immunotherapy platform capable of selectively
targeting cancer cells while preserving healthy tissue. These
innovations underscore the relentless pursuit of breakthroughs in
oncology to enhance patient outcomes. Among the key players driving
recent progress in the field are Oncolytics Biotech Inc.
(NASDAQ: ONCY) (TSX: ONC), Erasca, Inc. (NASDAQ: ERAS),
Allogene Therapeutics, Inc. (NASDAQ: ALLO), Context
Therapeutics Inc. (NASDAQ: CNTX), and Recursion
Pharmaceuticals, Inc. (NASDAQ: RXRX).
The article continued: The oncology field continues to advance,
with MarketsAndMarkets forecasting the Artificial
Intelligence in Oncology Market to reach $11.52 billion by 2030, driven by a 29.4% CAGR.
Similarly, Nova Advisor predicts the Personalized Cell
Therapy Market will grow at a 23.53% CAGR, reaching
$251.37 billion by 2034.
Oncolytics Biotech® Highlights 2024 Achievements and Prepares
for an Influential 2025 with Promising Breast and GI Cancer
Data
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a
leading clinical-stage company specializing in immunotherapy for
oncology, recently released a recap of major accomplishments
from 2024 and a preview of anticipated milestones for the next 12
months. Following the promising BRACELET-1 readout,
Oncolytics expects additional data readouts across its
clinical development program in 2025, forming what it believes is a
clear pathway to future commercialization opportunities.
"This past year produced highly encouraging clinical
developments that we believe set the stage for significant
progress, headlined by the robust efficacy results from the
BRACELET-1 breast cancer study," said Wayne
Pisano, Interim CEO and Chair of Oncolytics Biotech's
Board of Directors. "In addition, our gastrointestinal cancer
program continues to impress, resulting in meaningful
collaborations with well-respected experts in the field. Key
opinion leaders in both breast and GI cancers continue to be
excited by pelareorep's potential as we move into 2025. Based on
these insights from leading oncologists, we believe pelareorep has
the potential to become a transformational immunotherapy—and that
pelareorep-based combination therapies could accelerate our path
toward regulatory approval. We are very optimistic about our plans
for the next year, and we look forward to showcasing our latest
clinical progress early in the new year at the ASCO GI
Symposium—an event that could provide key catalysts for our
ongoing gastrointestinal cancer programs. Unlike many
immunotherapies that struggle to convert 'cold' tumors to 'hot,'
pelareorep's unique mechanism of action following intravenous
delivery has shown the potential to significantly boost patients'
immune responses—making previously unresponsive tumors more
susceptible to treatment. I would like to say thank you to our
shareholders, clinical collaborators, study sites and their staff,
the patients who participate in our trials, and the employees of
Oncolytics Biotech who have stepped up in a significant way
in the temporary absence of our CEO, Matt
Coffey."
Oncolytics Biotech continues to advance pelareorep, its
innovative immunotherapy for multiple cancer indications. Final
efficacy results from the BRACELET-1 study in HR+/HER2- metastatic
breast cancer demonstrated a median overall survival benefit
exceeding one year and a two-year survival rate nearly double that
of paclitaxel monotherapy. These findings, supported by earlier
IND-213 data, further reinforce pelareorep's transformative
potential. With FDA alignment on a planned
registration-enabling study, Oncolytics Biotech aims to
offer improved treatment options for approximately 55,000 U.S.
patients annually.
Significant progress has also been made in pancreatic cancer,
with plans for a registration-enabling study supported by
collaborations with the Global Coalition for Adaptive Research
(GCAR) and Roche. This follows the GOBLET study's outcomes,
which more than doubled response rates in first-line metastatic
pancreatic ductal adenocarcinoma (PDAC) patients. Additionally, the
PanCAN-funded GOBLET cohort evaluating pelareorep plus mFOLFIRINOX,
with or without atezolizumab, has completed safety run-in
enrollment, receiving positive feedback from the Data Safety
Monitoring Board. Key findings from this cohort, alongside progress
in anal cancer, will be presented at the ASCO GI Symposium
in January 2025.
Looking ahead, Oncolytics Biotech will present at the
Biotech Showcase on January 13, 2025,
and host investor meetings during the J.P. Morgan Healthcare
Conference that same week. These events will provide a platform to
highlight its clinical advancements and reinforce its commitment to
addressing critical unmet needs in oncology.
CONTINUED… Read this and more news for Oncolytics Biotech
at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the
market include:
Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision
oncology company, recently provided updates on its R&D
advancements targeting RAS/MAPK pathway-driven cancers. In
October 2024, the company presented
promising Phase 1b SEACRAFT-1 data
for naporafenib plus trametinib (MEKINIST®), showing potential for
an NRAS-mutated melanoma indication and supporting the ongoing
Phase 3 SEACRAFT-2 trial. Erasca also announced progress on
its pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor
ERAS-4001 programs, confirming best-in-class potential and
preparing for IND submissions in 2025. Key milestones include data
from SEACRAFT-2 in 2025 and initial Phase 1 monotherapy data for
ERAS-0015 and ERAS-4001 in 2026.
"We made significant progress across our pipeline programs and
are pleased with the pace of our execution," said Jonathan E. Lim, M.D., Chairman, CEO, and
co-founder of Erasca. "Positive preliminary data from
SEACRAFT-1, which we reported at the 36th EORTC-NCI-AACR (ENA)
Symposium last month, has refined our clinical development focus of
naporafenib plus trametinib on patients with NRAS-mutant (NRASm)
melanoma, and importantly, heightens our conviction in the ongoing
SEACRAFT-2 registrational trial targeting a similar patient
population. SEACRAFT-2 has the potential for approval based on the
high unmet need of these patients as well as the alignment with US
and European regulators on the NRASm melanoma indication. We expect
randomized dose optimization data from Stage 1 of this Phase 3
trial in 2025."
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a
clinical-stage biotechnology company, recently announced new
data from the Phase 1 TRAVERSE trial evaluating ALLO-316, its first
AlloCAR T™ product candidate, for advanced or metastatic renal cell
carcinoma (RCC). Presented at the 2024 IKCS and SITC
Annual Meetings, the data demonstrated a 50% overall response rate
(ORR) and a 33% confirmed response rate (CRR) in patients with CD70
Tumor Proportion Scores (TPS) ≥50%. ALLO-316 showed robust CAR T
cell expansion, manageable safety, and durable tumor responses,
supporting the FDA's RMAT designation for advanced RCC.
Additional data from the ongoing Phase 1b expansion cohort is expected in mid-2025.
"ALLO-316, the leading "off-the-shelf" CAR T product candidate
currently in development for solid tumors, continues to show
remarkable potency in the TRAVERSE trial," said Zachary Roberts, M.D., Ph.D., EVP, Research and
Development and Chief Medical Officer of Allogene. "Data
from the Phase 1 study demonstrating significant anti-tumor
activity in patients with metastatic disease resistant to multiple
therapeutic classes, even with standard lymphodepletion,
potentially marks a major advancement in the field. The
unprecedented cell expansion and persistence driven by CD70
CAR-intrinsic Dagger® technology, along with strong evidence of
tumor infiltration by CAR T cells, highlights the distinctive
features of ALLO-316. We believe these findings from our Phase 1
trial lay the groundwork for a new generation of allogeneic cell
therapies."
Context Therapeutics Inc. (NASDAQ: CNTX), a
biopharmaceutical company advancing T cell engagers for solid
tumors, recently announced advancements in its T cell-engaging
bispecific antibody pipeline, including CT-202, a Nectin-4 x CD3
antibody licensed in September 2024,
with an IND filing expected in mid-2026. Context also
acquired CT-95, a Mesothelin x CD3 antibody, set to begin Phase 1
trials in Q1 2025. Additionally, Context will present data
on its Claudin 6-targeting antibody CTIM-76 at the SITC
Annual Meeting.
"Context executed on its strategy to build a pipeline of
T cell engaging bispecific antibodies through its acquisitions of
CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a
Nectin-4 x CD3 bispecific antibody," said Martin Lehr, CEO of Context. "We continue
to activate additional sites for our Phase 1 trial for CTIM-76, a
Claudin 6 x CD3 bispecific antibody, and expect to dose our first
patient by the end of this year. We also expect to advance CT-95
into the clinic soon and expect to enroll our first patient in our
CT-95 Phase 1 study in the first quarter of 2025."
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a
clinical stage TechBio company, recently
announced interim data from the Phase 1/2 ELUCIDATE trial
of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.
The trial showed REC-617 was well-tolerated with no
discontinuations due to adverse events, and one patient with
platinum-resistant ovarian cancer achieved a confirmed partial
response lasting over six months, while four others had stable
disease for up to six months. With plans to continue dose
escalation and initiate combination studies in early 2025, REC-617
demonstrates potential as a safe and effective therapy in heavily
pre-treated cancer patients.
"Cell cycle dysregulation and transcriptional 'addiction' are
both hallmarks of many aggressive cancers," said David Hallett, Ph.D., Chief Scientific Officer
of Recursion. "By inhibiting CDK7, we have the potential to
target both mechanisms while fine tuning the therapeutic index.
Using our precision design platform, we created a molecule with
rapid oral absorption to reduce GI tissue exposure, a suitable half
life to manage side effects, and target engagement covering the
IC80 level."
Source:
https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Oncolytics Biotech Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of Oncolytics Biotech Inc., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
Oncolytics Biotech Inc. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of Oncolytics Biotech Inc. at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
Oncolytics Biotech Inc.; this is a paid advertisement, we currently
own shares of Oncolytics Biotech Inc. and will buy and sell shares
of the company in the open market, or through private placements,
and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
View original
content:https://www.prnewswire.com/news-releases/oncology-in-focus-how-emerging-therapies-are-reshaping-cancer-treatment-302339333.html
SOURCE USA News Group
